Product Sales, Net was Biocryst Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $548.78M of $569.40M (96%).
| Product and Service | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License & Other Revenues | — | — | — | $708.00K | ||||||||
| Product Sales, Net | — | $288.36M | $385.96M | $548.78M | ||||||||
| Revenues | $267.71M | — | — | — | ||||||||
| Product | — | — | — | — | ||||||||
| Orladeyo | $251.63M | — | — | — | ||||||||
| Other Revenues | $19.19M | $5.42M | $13.05M | — | ||||||||
| Milestone | — | — | — | — | ||||||||
| Collaborative & Other Revenues | $3.12M | — | — | $7.71M | ||||||||
| Collaborative & Other Research And Development | — | — | — | — | ||||||||
| Rapivab | — | — | $1.67M | $12.21M | ||||||||
| Royalty | — | — | — | — | ||||||||
| Total | $541.65M | $293.78M | $400.69M | $569.40M |
Biocryst Pharmaceuticals brought in $569.40M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Biocryst Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $400.69M. Product Sales, Net was the largest at $548.78M (96.4%), ahead of Rapivab at $12.21M (2.1%) and Collaborative & Other Revenues at $7.71M (1.4%). The remaining line, License & Other Revenues, brought in $708.00K.
Compared with fiscal 2024, Rapivab grew 630.0% to $12.21M and Product Sales, Net grew 42.2% to $548.78M.
Biocryst Pharmaceuticals began breaking out License & Other Revenues in fiscal 2025, when it brought in $708.00K. Biocryst Pharmaceuticals stopped reporting Revenues ($267.71M in fiscal 2022), Orladeyo ($251.63M in fiscal 2022) and Other Revenues ($13.05M in fiscal 2024) as separate lines.
U.S was Biocryst Pharmaceuticals’s largest region in fiscal 2023, bringing in $288.36M of $325.99M (88%).
| Geography | FY 2023 |
|---|---|
| U.S | $288.36M |
| Outside Of U.S | $37.63M |
| Total | $325.99M |
Biocryst Pharmaceuticals brought in $325.99M from its two regions in fiscal 2023, the year ended December 31, 2023. U.S was the largest at $288.36M (88.5%), ahead of Outside Of U.S at $37.63M (11.5%).
Biocryst Pharmaceuticals (BCRX) reports its revenue by product and service and by geography. In fiscal 2025, Product Sales, Net was its largest product and service line, bringing in $548.78M (96.4% of the total), followed by Rapivab at $12.21M (2.1%).
Product Sales, Net was Biocryst Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $548.78M, or 96.4% of the $569.40M total across its four product and service lines.
U.S was Biocryst Pharmaceuticals' largest region in fiscal 2023, bringing in $288.36M, or 88.5% of the $325.99M total across its two regions.
Every figure comes from Biocryst Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Biocryst Pharmaceuticals gives it, and years follow its fiscal calendar.
Biocryst Pharmaceuticals' revenue by product and service goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.